Latest Property Portfolio News

CDL Investments New Zealand reported a modest profit decline for the first half of 2026, reflecting ongoing residential market challenges, while securing a $20 million credit facility to support future development.

Charter Hall Social Infrastructure REIT (ASX:CQE) reported a 13.1% rise in operating earnings per unit for FY26, driven by strategic acquisitions and strong rental growth, while raising guidance for FY27.

Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial stays on track for November topline results, buoyed by strong open-label extension enrolment and aligned EMA-FDA regulatory advice. A new antidepressant study publication and fresh patents add momentum, supported by a $16.7 million cash runway to mid-2027.

Island Pharmaceuticals has marked a major step forward in its antiviral program with the start of GMP manufacturing for Galidesivir, expanded USAMRIID collaboration, and FDA orphan drug designation. Regulatory approvals for compassionate use in Uganda’s Ebola outbreak and a new dose optimisation study with Texas Biomed further de-risk the pathway to approval.

Desane Group Holdings progresses key developments in Penrith and Leichhardt, with construction milestones and tenant arrangements set to boost recurring income.

RAM Essential Services Property Fund (ASX: REP) has agreed to sell five retail properties to an institutional investor-backed fund, retaining a 10% stake and realising $218.6 million in value. The move reduces REP’s gearing to around 16% and rebalances its portfolio to 74% healthcare exposure.

Entropy Neurodynamics has expanded its global intellectual property portfolio with a South African patent for psilocybin-based fibromyalgia treatment, covering broad therapeutic methods and extending protection to 2043.

Mesoblast has completed treatment of 300 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain due to degenerative disc disease, with topline results expected mid-2027.

Temas Resources has filed a new patent for extracting chromium using its Regenerative Chloride Leach technology, broadening its critical minerals platform and commercial prospects.

Patrys has assigned its deoxymab intellectual property to Yale University in a deal granting it half of all future commercialisation revenue, reducing capital needs while keeping long-term upside.

Mesoblast Limited’s Ryoncil® posted US$36 million in Q4 revenue, driving a full-year total of US$115 million, exceeding initial forecasts. The FDA-approved stem cell therapy for pediatric graft-versus-host disease shows robust uptake across US pediatric centres.

Archer Materials made significant strides in quantum chip fabrication and quantum neural network fraud detection, while progressing its Biochip beta prototype. A $7 million placement post-quarter strengthens its financial position to accelerate development and commercialisation.